Parathyroid disorders

1. High-Yield Summary

• Central Regulator of Mineral Homeostasis: Parathyroid hormone (PTH) is an 84-amino acid polypeptide synthesized by parathyroid chief cells that maintains extracellular ionized calcium within a strict physiological range through coordinated actions on bone (osteocytic perilacunar remodeling and osteoblast-mediated osteoclastogenesis), the kidney (stimulated distal tubular calcium reabsorption, proximal tubular phosphaturia, and 1-alpha-hydroxylase activation), and the intestine (indirectly via calcitriol synthesis).
• Etiologic and Phenotypic Spectrum: Parathyroid pathology encompasses hyperfunctioning states (Primary Hyperparathyroidism (PHPT) resulting from solitary adenomas (~85%), multiglandular hyperplasia (~15%), or parathyroid carcinoma (<1%); Secondary Hyperparathyroidism (SHPT) resulting from chronic kidney disease-mineral bone disorder (CKD-MBD); Tertiary Hyperparathyroidism (THPT) resulting from autonomous nodular hyperplasia post-renal failure) and hypofunctioning states (Hypoparathyroidism, predominantly iatrogenic following total thyroidectomy or central neck dissection).
• Musculoskeletal Impact of High-Turnover Disease: Excessive, unremitting PTH secretion produces osteitis fibrosa cystica, characterized by high bone turnover, endosteal scalloping, subperiosteal cortical bone resorption (pathognomonic along the radial aspect of the 2nd and 3rd middle phalanges), granular “salt-and-pepper” skull demineralization, “rugger-jersey spine”, and focal destructive osteolytic lesions termed brown tumors (osteoclastomas).
• Brown Tumor Diagnostic Trap: Brown tumors are non-neoplastic, reactive osteolytic lesions filled with vascular fibrous tissue, hemosiderin, and multinucleated osteoclast-like giant cells that are histologically indistinguishable from giant cell tumors of bone (GCTB). Biopsy and primary oncologic resection are contraindicated; definitive cure of hyperparathyroidism leads to spontaneous remineralization and re-ossification within 6 to 12 months. Operative orthopaedic intervention is reserved strictly for impending or completed pathological fractures of weight-bearing long bones.
• Evidence-Based Surgical Thresholds: Per the 2022 Fifth International Workshop guidelines, parathyroidectomy is indicated for all symptomatic PHPT patients and asymptomatic individuals meeting defined criteria: age < 50 years; serum calcium > 1.0 mg/dL (>0.25 mmol/L) above the upper normal limit; T-score ≤ -2.5 at the lumbar spine, total hip, femoral neck, or distal 1/3 radius (or documented fragility/vertebral fracture); eGFR < 60 mL/min/1.73m2, 24-hour urine calcium > 250 mg/day (women) or > 300 mg/day (men), or nephrolithiasis/nephrocalcinosis on imaging.

2. Anatomy

The parathyroid glands are small, encapsulated, highly vascular endocrine organs, typically four in number (two superior and two inferior), located in close anatomical proximity to the posterior capsule of the thyroid gland. A thorough understanding of their complex embryological origins, anatomical landmarks, neurovascular relationships, and target-organ cellular biology is essential for accurate clinical evaluation and safe operative intervention.

Embryological Origins and Descent Patterns

• Superior Parathyroid Glands (Parathyroid IV): Arise from the dorsal wing of the fourth pharyngeal pouch alongside the ultimobranchial body (which incorporates into the thyroid gland as calcitonin-secreting parafollicular C cells). Because of their short migratory trajectory, their adult position is remarkably constant, with 80% to 85% found within a 1-cm radius posterior to the mid-to-upper third of the thyroid lobe, dorsal to the recurrent laryngeal nerve.
• Inferior Parathyroid Glands (Parathyroid III): Arise from the dorsal wing of the third pharyngeal pouch alongside the ventral thymic primordium. The developing inferior glands migrate caudally with the descending thymus. Because of this extended embryological descent, the inferior parathyroid glands exhibit substantial anatomical variation. While most come to rest along the posterolateral aspect of the lower thyroid pole or within the thyrothymic ligament, ectopic inferior glands may be located anywhere along the thymic descent pathway, including intrathymic (anterior mediastinum), within the carotid sheath, or high in the neck near the carotid bifurcation due to failed descent.

Anatomical Relationships and Vascular Pedicles

• The Coronal Plane Rule (Recurrent Laryngeal Nerve): The recurrent laryngeal nerve (RLN) serves as the critical coronal landmark during cervical exploration. The superior parathyroid gland almost invariably lies dorsal (posterior) to the coronal plane of the RLN, whereas the inferior parathyroid gland lies ventral (anterior) to the coronal plane of the RLN.
• Inferior Thyroid Artery Landmarks: Both superior and inferior parathyroid glands receive their predominant arterial blood supply from terminal branches of the inferior thyroid artery (ITA), with secondary collateral supply to the superior gland from the superior thyroid artery. The superior parathyroid gland typically resides cranial to the crossing of the inferior thyroid artery, whereas the inferior gland resides caudal to this junction.

Neurovascular Danger Zones and Surgical Planes

• Tracheoesophageal Groove & Recurrent Laryngeal Nerve: The RLN ascends within the tracheoesophageal groove, passing deep to the inferior thyroid artery before entering the larynx beneath the inferior constrictor muscle at the level of the cricothyroid articulation. During mobilization of superior or inferior parathyroid glands, traction, blind dissection, or indiscriminate use of monopolar electrocautery in this groove risks neuropraxia or permanent vocal cord paralysis.
• End-Artery Devascularization: Each parathyroid gland relies almost exclusively on a tiny, single end-arterial branch from the inferior or superior thyroid artery. Aggressive dissection or skeletonization of the thyroid capsule can disrupt this fragile end-vessel, resulting in parathyroid ischemia, necrosis, and postoperative hypoparathyroidism.
• Surgical Dissection Plane: The safe plane of dissection during parathyroidectomy is entered by dividing the strap muscles at the median raphe and sweeping the sternothyroid and sternohyoid muscles laterally. The thyroid lobe is rotated medially and anteriorly to expose the posterior capsule and tracheoesophageal groove, maintaining blunt, bloodless dissection strictly along the parathyroid capsule.

Molecular Physiology and Target-Organ Cellular Mechanisms

• PTH Synthesis & Calcium-Sensing Receptor (CaSR): PTH is synthesized as a 115-amino acid pre-pro-hormone within chief cells and cleaved to active intact PTH(1-84). Chief cell secretion is regulated by the cell-surface CaSR, a G-protein-coupled receptor. Binding of extracellular ionized calcium activates phospholipase C and inhibits adenylate cyclase, suppressing PTH secretion. A drop in extracellular calcium relieves CaSR inhibition, triggering immediate exocytosis of pre-formed PTH within seconds. Intact PTH has a short biological half-life of 3 to 5 minutes, forming the biochemical rationale for intraoperative PTH monitoring.
• Osteoblast-Mediated Osteoclastogenesis: Mature osteoclasts lack functional PTH receptors. PTH binds the Parathyroid Hormone 1 Receptor (PTH1R), a GPCR on osteoblasts, osteoprogenitors, and osteocytes. PTH1R activation stimulates cAMP and protein kinase A signaling, upregulating Receptor Activator of Nuclear Factor-kB Ligand (RANKL) while downregulating Osteoprotegerin (OPG). RANKL binds RANK on osteoclast precursors, driving osteoclast recruitment, differentiation, fusion, and activation, resulting in accelerated bone resorption.
• Osteocytic Perilacunar Remodeling: PTH directly stimulates osteocytes within deep cortical matrix to resorb their perilacunar envelope via secretion of tartrate-resistant acid phosphatase (TRAP), cathepsin K, and matrix metalloproteinase-13 (MMP-13), rapidly mobilizing skeletal calcium into the circulation.
• Renal Tubular Actions: In the distal convoluted tubule and thick ascending limb, PTH activates basolateral PTH1R to stimulate active calcium entry via apical TRPV5 channels and basolateral NCX1 extrusion. In the proximal tubule, PTH triggers internalization of sodium-phosphate cotransporters Npt2a and Npt2c, causing marked phosphaturia. Simultaneously, PTH directly upregulates mitochondrial 25-hydroxyvitamin D 1-alpha-hydroxylase (CYP27B1), converting 25(OH)D into active calcitriol [1,25(OH)2D].
• Intestinal Calcium Absorption (Indirect Action): PTH exerts no direct enterocyte effect. Instead, PTH-stimulated calcitriol binds the nuclear Vitamin D Receptor (VDR) in enterocytes of the duodenum and jejunum, upregulating apical TRPV6 channels, intracellular calbindin-D9k, and basolateral PMCA1b pumps, dramatically increasing fractional calcium and phosphate absorption.

3. Pathogenesis

Parathyroid disorders diverge into states of autonomous hormone hypersecretion, reactive physiological compensation, tertiary autonomous transformation, and deficient secretion. The resulting perturbations in systemic calcium-phosphate balance exert profound effects on bone remodeling kinetics and mineral density.

Primary Hyperparathyroidism (PHPT)

• Etiological Distribution: Characterized by autonomous, non-suppressible hypersecretion of PTH despite elevated extracellular ionized calcium. Solitary benign adenomas account for approximately 85% of cases; multiglandular disease (chief cell hyperplasia or double adenomas) accounts for approximately 15%; parathyroid carcinoma represents less than 1% of cases.
• Molecular Drivers: Sporadic adenomas frequently harbor clonal mutations in the MEN1 tumor suppressor gene (encoding menin) or pericentromeric rearrangements juxtaposing the PTH promoter with the CCND1 gene (leading to cyclin D1 / PRAD1 overexpression and uncontrolled chief cell proliferation).
• Familial Syndromes (MEN1 & MEN2A): In Multiple Endocrine Neoplasia Type 1 (MEN1, 11q13 mutation), nearly 100% of patients develop multiglandular parathyroid hyperplasia by age 50, alongside pituitary and pancreatic neuroendocrine tumors. In MEN2A (RET proto-oncogene mutation on 10q11.2), parathyroid hyperplasia occurs in 20% to 30% of patients, coexisting with medullary thyroid carcinoma and pheochromocytoma.
• Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome: Autosomal dominant inactivating germline mutations in HRPT2/CDC73 (encoding parafibromin on 1q31.2); carries a 15% lifetime risk of aggressive parathyroid carcinoma, cystic parathyroid adenomas, and bilateral ossifying fibromas of the mandible and maxilla.

Secondary & Tertiary Hyperparathyroidism

• Secondary Hyperparathyroidism (SHPT) in CKD-MBD: Represents a compensatory polyclonal parathyroid hyperplasia driven by chronic systemic hypocalcemia, hyperphosphatemia, and impaired calcitriol synthesis. As functional nephron mass declines (GFR < 60 mL/min/1.73m2), impaired renal phosphate clearance causes progressive phosphate retention. Early elevation of osteocytic FGF-23 potently suppresses proximal tubular 1-alpha-hydroxylase, creating severe calcitriol deficiency and hypocalcemia. Downregulation of parathyroid VDR and CaSR removes negative feedback loops, driving persistent parathyroid hyperplasia and massive PTH secretion.
• Tertiary Hyperparathyroidism (THPT): Develops in patients with longstanding end-stage secondary hyperparathyroidism on chronic hemodialysis or persisting after renal transplantation. Chronic polyclonal hyperplasia transitions into autonomous, monoclonal nodular hyperplasia. The chief cells exhibit profound down-regulation of CaSR and VDR surface receptors, becoming completely resistant to extracellular calcium suppression. PTH hypersecretion persists autonomously, producing severe hypercalcemia that fails to normalize even after successful kidney transplantation.

Hypoparathyroidism

• Iatrogenic Post-Surgical Etiology: Inadvertent surgical resection, thermal injury, or devascularization of all four parathyroid glands during total thyroidectomy, central neck dissection, or repeat parathyroidectomy accounts for over 75% of all hypoparathyroidism cases.
• Autoimmune Polyglandular Syndrome Type 1 (APS-1 / APECED): Caused by mutations in the AIRE gene on chromosome 21q22.3; presents with the classic triad of chronic mucocutaneous candidiasis, autoimmune hypoparathyroidism, and Addison disease.
• Developmental & Genetic Disorders: DiGeorge syndrome (22q11.2 deletion syndrome) results from defective neural crest migration into the third and fourth pharyngeal pouches, leading to congenital parathyroid aplasia, thymic hypoplasia, and conotruncal cardiac malformations. Autosomal Dominant Hypocalcemia Type 1 (ADH1) arises from gain-of-function activating mutations in the CASR gene, causing constitutional suppression of PTH secretion and hypocalcemia with inappropriate hypercalciuria.

Musculoskeletal Manifestations of High-Turnover Bone Disease

• Osteitis Fibrosa Cystica: Unchecked, chronic PTH elevation uncouples bone remodeling, accelerating both osteoclastic bone resorption and osteoblastic bone formation, with catabolism heavily predominating. The normal haversian cortical architecture is replaced by widespread osteoclastic tunneling. Bone marrow spaces are replaced by dense, highly vascular fibroblastic connective tissue (peritrabecular marrow fibrosis).
• Brown Tumors (Osteoclastomas): In advanced, longstanding osteitis fibrosa cystica, localized zones of intense, rapid osteoclastic bone resorption experience microfractures and micro-vascular disruption. Hemorrhage into the osteolytic cavity is followed by erythrocyte breakdown and extensive deposition of hemosiderin pigment. Histologically, these lesions consist of sheets of multinucleated osteoclast-like giant cells embedded within a richly vascular, spindle-cell fibroblastic stroma. The gross accumulation of hemosiderin imparts the characteristic chocolate-brown appearance. Brown tumors are non-neoplastic, locally expansile lesions that possess no intrinsic malignant potential.
• Subperiosteal Cortical Resorption: The hallmark radiographic manifestation of high-turnover bone disease. Osteoclasts beneath the fibrous periosteum selectively excavate the outer cortical margin, producing lace-like cortical scalloping, most prominent along the radial aspect of the middle phalanges.
• Rugger-Jersey Spine: In secondary and tertiary hyperparathyroidism associated with renal osteodystrophy, sustained PTH elevation induces excessive, disorganized osteoid deposition adjacent to the superior and inferior vertebral endplates. This creates wide bands of sclerotic bone that contrast sharply with the central radiolucent, osteopenic mid-vertebral body, mimicking the horizontal stripes of a rugby jersey.
• Salt-and-Pepper Skull & Acro-osteolysis: Loss of the sharp distinction between the inner and outer cortical tables of the calvarium, characterized by diffuse granular osteopenia peppered with small, rounded radiolucent resorption foci. Resorption of the distal phalangeal terminal tufts produces pencil-pointing or pseudoclubbing of the digits.
• Chondrocalcinosis / Pseudogout: Chronic hypercalcemia and altered pyrophosphate metabolism predispose to the precipitation of calcium pyrophosphate dihydrate (CPPD) crystals within articular hyaline cartilage and fibrocartilage (especially the knee menisci and triangular fibrocartilage complex of the wrist), precipitating acute inflammatory crystal synovitis.

4. Natural History & Epidemiology

Primary hyperparathyroidism is the most common cause of outpatient hypercalcemia in clinical practice, with an estimated prevalence of 1 to 4 per 1,000 individuals and an annual incidence of 50 per 100,000 person-years. The condition demonstrates a marked female-to-male predilection of approximately 3:1, with peak incidence occurring in postmenopausal women between 55 and 65 years of age. Conversely, secondary hyperparathyroidism affects virtually all patients with end-stage renal disease (ESRD) requiring long-term dialysis, while post-surgical hypoparathyroidism accounts for over 75% of chronic hypoparathyroid cases worldwide.

If left untreated, parathyroid disorders follow distinct, debilitating trajectories:

• Progressive Cortical Bone Loss: In primary hyperparathyroidism, continuous PTH secretion selectively accelerates intracortical remodeling, causing preferential thinning and porosity of cortical bone compared to trabecular bone. As a result, cortical bone mineral density (measured at the distal 1/3 radius and femoral neck) declines progressively. Patients suffer a two- to threefold increase in relative risk for fragility fractures of the hip, distal forearm, and spine.
• Renal & Endothelial Complications: Untreated hypercalcemia and hypercalciuria culminate in recurrent calcium oxalate and calcium phosphate nephrolithiasis in 15% to 20% of patients, extensive nephrocalcinosis, and progressive tubulointerstitial renal dysfunction. Chronic hypercalcemia is independently associated with arterial stiffness, endothelial dysfunction, left ventricular hypertrophy, and elevated cardiovascular mortality.
• Progression of Renal Osteodystrophy & Calciphylaxis: In untreated secondary or tertiary hyperparathyroidism, skeletal turnover remains dangerously uncoupled, leading to profound bone pain, severe multi-site fragility fractures, and spontaneous avulsions of the quadriceps or patellar tendons from osteopenic entheses. Patients face high risks of calcific uremic arteriolopathy (calciphylaxis), a devastating small-vessel calcification and thrombotic occlusion syndrome characterized by painful, non-healing ischemic skin ulcerations and subcutaneous fat necrosis, carrying a 1-year mortality rate exceeding 50%.
• Chronic Hypoparathyroidism Morbidity: Untreated or inadequately managed hypoparathyroidism produces chronic neuromuscular tetany, cognitive dysfunction, cataracts from calcium precipitation within the lens, basal ganglia calcification (Fahr syndrome) causing extrapyramidal movement disorders, and renal failure secondary to chronic hypercalciuria and nephrocalcinosis induced by oral calcium supplementation without PTH action.

5. Clinical Presentation

History

In modern clinical practice across industrialized nations, over 80% of patients with primary hyperparathyroidism are asymptomatic at diagnosis, discovered serendipitously during routine automated biochemical screening demonstrating elevated serum total or ionized calcium. When clinical manifestations occur, they span the classical historical pentad: “stones, bones, abdominal groans, psychic moans, and fatigue overtones.”

• Renal (“Stones”): Recurrent nephrolithiasis, sharp colicky flank pain radiating to the groin, macroscopic or microscopic hematuria, polyuria, and polydipsia resulting from calcium-induced nephrogenic diabetes insipidus.
• Skeletal (“Bones”): Deep, diffuse, aching bone pain, focal skeletal tenderness overlying expanding brown tumors, sudden acute pain indicating a pathological fracture, progressive loss of height, and dorsal kyphosis secondary to silent vertebral compression fractures.
• Gastrointestinal (“Abdominal Groans”): Chronic obstipation or constipation, generalized nausea, anorexia, dyspepsia from peptic ulcer disease (calcium stimulates gastrin secretion and parietal cell acid production), and acute pancreatitis (calcium activates trypsinogen to trypsin within pancreatic parenchyma).
• Neuropsychiatric (“Psychic Moans”): Chronic cognitive blunting, memory deficits, depression, emotional lability, anxiety, daytime somnolence, delirium, and, in severe hypercalcemic crises, stupor or coma.
• Neuromuscular (“Fatigue Overtones”): Profound physical exhaustion, daytime asthenia, and progressive proximal muscle weakness, particularly affecting the pelvic and shoulder girdles (difficulty climbing stairs, rising from low chairs, or lifting objects overhead).
• Hypoparathyroidism Symptoms: Patients complain of perioral numbness, circumoral tingling, paresthesias of the fingers and toes, painful involuntary muscle cramps, carpopedal spasms, dyspnea or laryngeal stridor (laryngospasm), and grand mal seizures during acute hypocalcemic drops.

Physical Exam

Physical examination must systematically assess musculoskeletal integrity, motor power, anterior cervical anatomy, and neuromuscular excitability.

• Musculoskeletal Palpation: Palpate for localized bony point tenderness or expansile cortical fullness over the pelvis, femur, tibia, ribs, and clavicles, which heralds impending brown tumor fractures. Assess spinal alignment for localized spinous process tenderness and thoracic hyperkyphosis.
• Proximal Motor Strength: Formally test proximal muscle power against resistance (Medical Research Council [MRC] scale). Symmetrical weakness of the hip flexors, quadriceps, and deltoid muscles with normal distal motor power and intact deep tendon reflexes is characteristic of hypercalcemic proximal myopathy.
• Anterior Neck Palpation: Inspect for previous thyroidectomy or parathyroidectomy scars. Normal parathyroid glands and benign adenomas are soft, small, and situated deep to the thyroid parenchyma; they are palpable in fewer than 5% of cases. The presence of a firm, hard, fixed, or palpable cervical mass strongly suggests parathyroid carcinoma, coexisting thyroid malignancy, or large multinodular goiter.
• Chvostek Sign: [Tapping the facial nerve trunk approximately 2 cm anterior to the external auditory meatus and ear lobe, just inferior to the zygomatic arch] -> Positive Finding: Involuntary ipsilateral contraction or twitching of facial muscles, ranging from subtle twitching of the upper lip and oral commissure to intense spasm of the entire facial hemiface [Sensitivity ~28%, Specificity ~92%]. (Note: A mild positive response is present in up to 10% of healthy normocalcemic individuals).
• Trousseau Sign: [Inflation of a standard sphygmomanometer blood pressure cuff on the upper arm to 20 mmHg above the patient’s systolic blood pressure, maintained continuously for 3 minutes] -> Positive Finding: Painful carpopedal spasm characterized by flexion of the wrist, flexion of the metacarpophalangeal joints, extension of the interphalangeal joints, and adduction of the thumb into the palm (the classic “obstetrician’s hand” or main d’accoucheur) [Sensitivity ~94%, Specificity ~99%].

6. Imaging and Diagnostic Studies

The diagnosis of parathyroid disorders is fundamentally biochemical. Radiographic and nuclear medicine imaging studies are utilized to identify end-organ skeletal damage and localize abnormal parathyroid tissue prior to operative exploration.

Biochemical Profiling and Diagnostic Ratios

• Serum Total and Ionized Calcium: Total calcium must always be corrected for albumin concentration using the formula: Corrected Calcium (mg/dL) = Measured Calcium (mg/dL) + 0.8 * [4.0 – Serum Albumin (g/dL)]. Serum ionized calcium (free biologically active fraction) represents the definitive gold standard and must be measured to detect hypercalcemia in patients with altered serum proteins, nephrotic syndrome, or cirrhosis.
• Intact Parathyroid Hormone (iPTH): Measured via second- or third-generation immunoradiometric assays (IRMA). In primary hyperparathyroidism, intact PTH is elevated (in ~85-90% of cases) or inappropriately normal (in ~10-15% of cases) in the face of hypercalcemia. A “normal” PTH in a hypercalcemic patient is fundamentally abnormal, reflecting failure of the parathyroid gland to suppress hormone release.
• Serum Phosphorus & Vitamin D Metabolites: Typically low (<2.5 mg/dL) or low-normal in PHPT due to PTH-induced renal phosphaturia; markedly elevated in secondary hyperparathyroidism from CKD due to impaired filtration. 25-hydroxyvitamin D [25(OH)D] must be measured in all patients to identify coexisting nutritional deficiency. Biologically active 1,25-dihydroxyvitamin D [1,25(OH)2D, calcitriol] is typically high-normal or elevated in PHPT due to PTH-driven 1-alpha-hydroxylase stimulation, but low in CKD.
• Alkaline Phosphatase (ALP): Total and bone-specific alkaline phosphatase reflect osteoblastic activity. Markedly elevated ALP indicates aggressive high-turnover bone disease and serves as the single strongest preoperative predictor of postoperative hungry bone syndrome.
• 24-Hour Urine Calcium & Calcium-to-Creatinine Clearance Ratio (CCCR): Mandatory prior to any surgical intervention to distinguish Primary Hyperparathyroidism from Familial Hypocalciuric Hypercalcemia (FHH). The CCCR is calculated as: CCCR = [24-hr Urine Calcium (mg/dL) * Serum Creatinine (mg/dL)] / [Serum Calcium (mg/dL) * 24-hr Urine Creatinine (mg/dL)]. A CCCR < 0.01 is highly diagnostic of FHH (inactivating CASR mutation; surgery contraindicated). A CCCR > 0.02 confirms Primary Hyperparathyroidism (24-hour urine calcium typically > 250 mg/day in women, > 300 mg/day in men). Values between 0.01 and 0.02 represent an indeterminate grey zone requiring genetic testing for CASR mutations.

Radiographic Hallmarks and Bone Mineral Density

• Subperiosteal Cortical Resorption: The pathognomonic radiological sign of hyperparathyroidism. Most sensitively visualized along the radial aspect of the middle phalanges of the 2nd and 3rd digits on high-resolution magnification radiographs of the hands. Appears as irregular, lace-like cortical scalloping and ragged loss of sharp cortical borders.
• Terminal Tuft Resorption & Calvarial Demineralization: Resorption of the distal phalangeal tufts (acro-osteolysis) produces a tapered, pencil-point configuration. Skull radiographs demonstrate the “salt-and-pepper” appearance: granular calvarial demineralization with mottled radiolucencies interspersed among dense bony trabeculae.
• Rugger-Jersey Spine: Characteristic of renal osteodystrophy (secondary and tertiary hyperparathyroidism). Lateral thoracolumbar films demonstrate dense horizontal sclerotic bands adjacent to the superior and inferior endplates sandwiching a central radiolucent, osteopenic vertebral body.
• Brown Tumors (Osteoclastomas): Well-circumscribed, eccentric, expansile osteolytic lesions with thinned, scalloped cortices and no internal matrix calcification or periosteal reaction. Common skeletal sites include the mandible, facial bones, pelvis, ribs, proximal femur, and tibia.
• Chondrocalcinosis: Fine, punctate, linear radiodense lines within the fibrocartilage of the knee menisci, triangular fibrocartilage complex (TFCC) of the wrist, and pubic symphysis.
• Bone Mineral Densitometry (DEXA) Protocol: Continuous PTH elevation selectively accelerates cortical bone remodeling. Consequently, bone densitometry reveals a classic discordance: the distal 1/3 (33%) radius (which is >95% cortical bone) demonstrates the lowest T-score, whereas the lumbar spine (predominantly trabecular bone) is relatively preserved. Comprehensive evaluation must always include three distinct anatomical regions: lumbar spine (L1-L4), total hip / femoral neck, and the non-dominant distal 1/3 radius.

Preoperative Parathyroid Localization Modalities

• Dual-Phase 99mTc-Sestamibi Scintigraphy & SPECT/CT: Technetium-99m sestamibi concentrates within the mitochondria of both thyroid follicular cells and parathyroid cells. Sestamibi washes out rapidly from normal thyroid parenchyma within 60 to 90 minutes, but is retained within mitochondria-rich oxyphil cells of parathyroid adenomas on delayed images. Hybrid SPECT/CT provides precise 3D anatomical localization relative to cervical vascular structures. Sensitivity is 80% to 90% for solitary adenomas, but drops to 30% to 50% in multiglandular disease.
• High-Resolution Neck Ultrasound: Uses 10-15 MHz linear transducers to identify parathyroid adenomas as well-defined, homogeneous, hypoechoic, oval soft tissue nodules situated posterior to the thyroid poles, often demonstrating a characteristic polar feeding artery on color Doppler. Sensitivity is 70% to 85% in experienced hands, but ultrasound cannot image retrosternal, mediastinal, or retroesophageal ectopic glands.
• Four-Dimensional Computed Tomography (4D-CT): Multiphase contrast-enhanced CT (unenhanced, early arterial, and delayed venous phases) leveraging perfusion kinetics. Parathyroid adenomas demonstrate rapid arterial enhancement followed by rapid venous washout, distinguishing them from thyroid tissue and lymph nodes. 4D-CT provides superior spatial resolution (sensitivity >90-95%) and is the modality of choice for re-operative cases, discordant ultrasound/sestamibi, and ectopic mediastinal glands.

7. Classification

Parathyroid disorders are classified based on their underlying physiological mechanisms, biochemical profiles, and secondary musculoskeletal manifestations. The following validated diagnostic framework delineates these distinct entities:

8. Treatment

Medical / Nonoperative

Medical management aims to control life-threatening hypercalcemia, suppress compensatory parathyroid hyperplasia, manage chronic kidney disease mineral bone disorder, or replace deficient calcium and parathyroid hormone.

• Acute Severe Hypercalcemia Protocol: Vigorous isotonic 0.9% normal saline hydration administered at 200 to 300 mL/hr to restore intravascular volume, enhance renal perfusion, and promote urinary sodium-calcium excretion. Furosemide (20 to 40 mg IV) is administered only after complete intravascular volume repletion has been achieved; administering diuretics before volume resuscitation worsens dehydration and elevates serum calcium. Intravenous zoledronic acid (4 mg infused over 15 minutes) potently inhibits osteoclast-mediated bone resorption, with onset at 48 to 72 hours. Salmon calcitonin (4 to 8 IU/kg subcutaneously or intramuscularly every 12 hours) provides a temporary therapeutic bridge while awaiting bisphosphonate effect, lowering serum calcium within 2 to 4 hours before tachyphylaxis occurs at 48 hours.
• Calcimimetics (Cinacalcet & Etelcalcetide): Cinacalcet is an oral allosteric activator of the calcium-sensing receptor (CaSR). By increasing chief cell CaSR sensitivity to extracellular calcium, cinacalcet suppresses PTH synthesis and secretion without increasing serum calcium or phosphate. Indicated for severe hypercalcemia in PHPT patients who are not surgical candidates, parathyroid carcinoma, and dialysis-dependent CKD secondary hyperparathyroidism. Etelcalcetide is an intravenous peptide calcimimetic administered three times weekly at the end of hemodialysis sessions, providing superior PTH suppression in advanced secondary hyperparathyroidism.
• Phosphate Binders & Active Vitamin D Sterols: Non-calcium phosphate binders (sevelamer carbonate, lanthanum carbonate) bind dietary phosphate within the gastrointestinal lumen without augmenting systemic calcium load, preventing hyperphosphatemia and vascular calcification in CKD-MBD. Active vitamin D analogs (calcitriol, paricalcitol) suppress PTH gene transcription in secondary hyperparathyroidism; serum calcium and phosphorus must be monitored closely to maintain the calcium-phosphate product (Ca x P) below 55 mg2/dL2.
• Antiresorptive Therapy in PHPT: Oral alendronate (70 mg weekly) improves lumbar spine and total hip bone mineral density in asymptomatic PHPT patients who decline or have contraindications to parathyroidectomy. Denosumab (60 mg subcutaneously every 6 months) potently inhibits RANKL-mediated bone resorption; however, it carries an FDA Boxed Warning (2024) for severe, refractory, life-threatening hypocalcemia in patients with advanced CKD and ESRD.
• Hypoparathyroidism Replacement Therapy: Conventional management relies on oral calcium carbonate or calcium citrate (1.0 to 3.0 g elemental calcium daily in divided doses) combined with active calcitriol (0.25 to 2.0 mcg daily). The therapeutic objective is to maintain serum calcium in the low-normal range (8.0 to 8.5 mg/dL) to prevent tetany while avoiding hypercalciuria (24-hour urine calcium > 300 mg/day) and subsequent nephrocalcinosis or chronic renal failure. Novel replacement therapy with TransCon PTH (palopegteriparatide), a once-daily prodrug providing sustained 24-hour physiologic PTH exposure, significantly normalizes serum calcium, eliminates conventional calcium/calcitriol requirements in over 90% of patients, and restores normal bone remodeling kinetics.

Operative

Surgical parathyroidectomy is the only definitive curative therapy for primary hyperparathyroidism, successfully normalizing biochemical parameters, increasing bone mineral density, arresting stone formation, and reversing high-turnover bone lesions.

• Goals of Surgery: Completely eradicate hyperfunctioning parathyroid tissue while preserving at least one functional, well-vascularized parathyroid remnant to prevent permanent hypoparathyroidism; identify and protect the recurrent laryngeal nerve and external branch of the superior laryngeal nerve throughout cervical dissection; and achieve permanent normocalcemia to facilitate spontaneous remineralization of parathyroid-related bone disease.
• Focused Minimally Invasive Parathyroidectomy (MIP): Indicated when preoperative localization imaging demonstrates concordant findings (e.g., both ultrasound and 99mTc-sestamibi SPECT/CT identify a single diseased gland). Performed through a 2.0 to 2.5 cm targeted transverse cervical incision directly overlying the adenoma. The dissection is carried out along the avascular capsule of the adenoma, with meticulous clip ligation of its end-arterial branch.
• Intraoperative PTH Monitoring & The Miami Criterion: MIP relies on the short 3- to 5-minute half-life of intact PTH. A baseline venous blood sample is drawn immediately prior to skin incision or manipulation of the gland. Following surgical excision of the suspected adenoma, blood samples are drawn at 5 and 10 minutes post-excision. The Miami criterion: a decrease in intact PTH of greater than 50% from the highest baseline value at 10 minutes post-excision predicts complete cure with >97% accuracy. If ioPTH fails to drop by >50%, immediate intraoperative conversion to formal bilateral neck exploration is mandatory.
• Bilateral Neck Exploration (BNE): Performed through a conventional low collar Kocher incision. Indicated for negative or discordant preoperative imaging, suspected multiglandular hyperplasia, MEN syndromes, familial hyperparathyroidism, or failed ioPTH drop during MIP. Requires systematic visualization and assessment of all four parathyroid locations.
• Subtotal vs. Total Parathyroidectomy with Autotransplantation: Subtotal parathyroidectomy (resection of 3.5 glands leaving a 30 to 50 mg vascularized remnant marked with a titanium clip) is standard for multiglandular hyperplasia. Total parathyroidectomy with immediate autotransplantation of 20 to 30 mg of minced parathyroid tissue into the brachioradialis muscle of the non-dominant forearm is favored in renal osteodystrophy and MEN1, allowing subsequent graft re-excision under local anesthesia without redo neck exploration if tertiary hyperparathyroidism recurs.
• Orthopaedic Management of Brown Tumors: The definitive and primary treatment of brown tumors is metabolic cure via parathyroidectomy. Following successful parathyroidectomy, cessation of high PTH levels prompts immediate osteoclast apoptosis, robust osteoblastic remineralization, and spontaneous re-ossification of the osteolytic defect within 6 to 12 months. Diagnostic biopsy is strictly contraindicated in confirmed hyperparathyroidism; biopsy yields no distinct oncologic information, risks severe hemorrhage from hypervascular tissue, introduces fracture risk, and histologically mimics giant cell tumor of bone. Mechanical stabilization (intramedullary nailing) is reserved strictly for impending or completed pathological fractures of weight-bearing long bones (Mirels score ≥ 8).

Indications & Contraindications

Surgical parathyroidectomy is indicated for all patients with clinically symptomatic primary hyperparathyroidism. For asymptomatic primary hyperparathyroidism, objective numerical thresholds dictate surgical indications based on the Fifth International Workshop Guidelines (2022):

• Age Threshold: Age < 50 years.
• Serum Calcium Threshold: Serum calcium > 1.0 mg/dL (>0.25 mmol/L) above the upper reference limit of normal.
• Skeletal Indications: Bone mineral density T-score ≤ -2.5 at the lumbar spine, total hip, femoral neck, or distal 1/3 (33%) radius; documented vertebral fragility fracture identified on spinal radiography or vertebral fracture assessment (VFA); or history of low-trauma fragility fracture.
• Renal Indications: Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2; 24-hour urine calcium excretion > 250 mg/day in women or > 300 mg/day in men; or presence of nephrolithiasis or nephrocalcinosis on renal ultrasound, CT scan, or abdominal radiograph.
• Indications in Secondary / Tertiary Hyperparathyroidism: Intractable hyperparathyroidism with intact PTH > 800 pg/mL persistent for >6 months despite maximal medical therapy; persistent hypercalcemia or hyperphosphatemia with calcium-phosphate product (Ca x P) > 55 to 65 mg2/dL2; progressive renal osteodystrophy (severe bone pain, brown tumors, tendon ruptures, multiple fractures); or calcific uremic arteriolopathy (calciphylaxis).
• Contraindications to Parathyroidectomy: Absolute contraindications include Familial Hypocalciuric Hypercalcemia (FHH), where surgery does not resolve hypercalcemia and results in permanent hypoparathyroidism, and severe uncompensated cardiopulmonary disease precluding general anesthesia. Relative contraindications include severe uncorrected vitamin D deficiency (25(OH)D < 20 ng/mL) coexisting with mild hypercalcemia, and discordant localization studies in the hands of a surgeon lacking formal 4-gland bilateral exploration training.

9. Outcome

Successful parathyroidectomy produces dramatic, sustained improvements in skeletal remineralization, fracture incidence, stone recurrence, and health-related quality of life.

• Bone Mineral Density Recovery: Surgical excision of hyperfunctioning parathyroid tissue prompts immediate cessation of pathologically high osteoclast bone resorption. In prospective long-term cohorts (Silverberg et al.), parathyroidectomy produces rapid, significant increases in bone mineral density: an 8% to 12% gain at the lumbar spine and a 10% to 14% gain at the femoral neck within 1 to 5 years, with continued stability over 10 years of longitudinal follow-up. Cortical bone mineral density at the distal 1/3 radius demonstrates progressive, steady improvements over several years.
• Fracture Risk Reduction: Population-based registry data and prospective trials demonstrate a 30% to 50% relative risk reduction in both vertebral compression and non-vertebral fragility fractures (including hip and distal radius fractures) within 2 to 5 years post-parathyroidectomy compared to matched non-operated patients.
• Spontaneous Remission of Osteolytic Lesions: Subperiosteal cortical resorption lines along the phalanges reconstitute completely within 6 months. Expansile brown tumors undergo robust internal sclerosis, trabecular consolidation, and cortical re-ossification within 6 to 12 months postoperatively, eliminating the need for direct orthopaedic resection or bone grafting.
• Renal & Neurocognitive Outcomes: The incidence of recurrent nephrolithiasis decreases by over 80% to 90% following curative parathyroidectomy. Validated patient-reported outcome measures (SF-36, Parathyroid Assessment of Symptoms [PAS]) demonstrate marked, sustained relief of chronic fatigue, proximal muscle weakness, sleep disturbances, and neurocognitive depression within 6 to 12 months.

10. Complications

Surgical complications associated with parathyroid disorders range from acute electrolyte crises to neurovascular injury and persistent metabolic disease.

11. Pearls and Pitfalls

• The CCCR Rule to Prevent Unnecessary Surgery: Never proceed to parathyroidectomy without calculating the Calcium-to-Creatinine Clearance Ratio (CCCR) from a 24-hour urine collection. A CCCR < 0.01 is diagnostic of Familial Hypocalciuric Hypercalcemia (FHH). Parathyroidectomy in FHH does not normalize calcium levels and exposes the patient to the devastating complication of permanent hypoparathyroidism.
• Mandatory Distal 1/3 Radius DEXA: Always order a dedicated distal 1/3 (33%) radius scan when performing dual-energy X-ray absorptiometry for hyperparathyroidism. Because PTH preferentially drives cortical bone catabolism over trabecular bone, standard lumbar spine and femoral neck T-scores may appear normal or falsely elevated by degenerative osteophytes, while the distal radius reveals severe osteoporosis (T-score ≤ -2.5), fulfilling surgical criteria.
• The Brown Tumor Histological Trap: Brown tumors and giant cell tumors of bone (GCTB) are histologically indistinguishable on biopsy, as both feature abundant multinucleated osteoclast-like giant cells within a spindle-cell stroma. Never perform curettage, bone grafting, or oncologic resection on a giant cell-rich bone lesion without first evaluating serum calcium, intact PTH, and alkaline phosphatase. Curing the hyperparathyroidism leads to spontaneous remineralization of brown tumors without orthopaedic surgery.
• Prophylactic Calcitriol Loading for Hungry Bone Syndrome: In patients with marked preoperative elevation of alkaline phosphatase (>3 to 4 times the upper limit of normal), extensive osteitis fibrosa cystica, or multiple brown tumors, hungry bone syndrome is virtually guaranteed. Initiate oral calcitriol (0.5 to 1.0 mcg daily) 48 to 72 hours prior to neck surgery and ensure serum magnesium is normalized to prevent refractory postoperative hypocalcemia.
• Denosumab Catastrophe in Advanced CKD: Avoid initiating denosumab in patients with advanced chronic kidney disease (CKD stage 4 or 5) or tertiary hyperparathyroidism without intense clinical monitoring. Denosumab causes rapid, profound, prolonged hypocalcemia in high-turnover renal bone disease that can be fatal and refractory to conventional calcium replacement.
• Avoid Sestamibi False Security in Multiglandular Disease: Do not rely exclusively on 99mTc-sestamibi SPECT/CT in patients with MEN1, secondary hyperparathyroidism, or tertiary hyperparathyroidism. Sestamibi often lights up a single dominant hyperplastic gland while failing to identify smaller enlarged glands, leading to inadequate resection and persistent hypercalcemia if minimally invasive surgery is attempted instead of bilateral neck exploration.

12. Controversy

• Parathyroidectomy vs. Observation in Mild Asymptomatic PHPT: While the 2022 Fifth International Workshop established explicit surgical thresholds for asymptomatic primary hyperparathyroidism, controversy persists regarding whether all patients with mild PHPT should undergo surgery regardless of age or bone density criteria. Proponents of universal surgical intervention argue that minimally invasive parathyroidectomy achieves >98% cure rates with outpatient recovery, arrests subclinical cortical bone loss, improves unrecognized neurocognitive blunting, and reduces long-term cardiovascular stiffness. Opponents advocate for conservative biochemical monitoring, citing prospective natural history cohorts demonstrating that up to 75% of patients over age 50 with mild hypercalcemia maintain stable serum calcium, renal function, and bone mineral density over 10 to 15 years without developing clinical complications.
• Subtotal Parathyroidectomy vs. Total Parathyroidectomy with Autotransplantation vs. Cinacalcet for Tertiary / Refractory Secondary Hyperparathyroidism: Substantial surgical disagreement exists regarding the optimal operative strategy for dialysis-dependent patients with severe secondary hyperparathyroidism or tertiary hyperparathyroidism. Subtotal parathyroidectomy (3.5-gland resection) preserves a native vascularized remnant, resulting in a lower incidence of severe postoperative hypoparathyroidism and adynamic bone disease. However, if hyperparathyroidism recurs, re-exploring the scarred neck carries a 5% to 10% risk of permanent vocal cord paralysis. Conversely, total parathyroidectomy with forearm autotransplantation allows subsequent re-resections of hyperplastic graft tissue under local anesthesia in the extremity, but carries a higher risk of initial graft failure and permanent hypoparathyroidism. Concurrently, medical calcimimetics (cinacalcet) provide non-surgical PTH suppression, but the randomized PROCEED trial demonstrated that surgical parathyroidectomy achieves significantly greater gains in femoral neck and lumbar spine bone mineral density than oral cinacalcet, questioning the long-term reliance on medical therapy alone.
• Timing and Indications for Orthopaedic Stabilization of Brown Tumors: The timing of orthopaedic intervention for brown tumors involving weight-bearing long bones remains debated. Proponents of early prophylactic internal fixation argue that waiting 6 to 12 months for metabolic remineralization post-parathyroidectomy places patients at unacceptable risk for sudden catastrophic pathological fracture during daily activities, particularly when cortical destruction exceeds 50% of bone diameter (Mirels score ≥ 8). Conversely, proponents of nonoperative protected weight-bearing emphasize that operating on acutely resorbed, osteopenic, hypervascular bone carries high risks of severe intraoperative bleeding, hardware loosening, and cut-out. They maintain that protected partial weight-bearing with crutches or bracing allows rapid osteoblastic remineralization to begin within weeks of parathyroidectomy, rendering surgical fixation unnecessary in most patients.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Bilezikian JP, Khan AA, Silverberg SJ et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022. doi:10.1002/jbmr.4677 [Level I: Systematic Review / Meta-Analysis]
• Mannstadt M, Cianferotti L, Gafni RI et al. Hypoparathyroidism: Genetics and Diagnosis. J Bone Miner Res. 2022. doi:10.1002/jbmr.4667 [Level I: Systematic Review / Meta-Analysis]
• Clarke BL, Khan AA, Rubin MR et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025. doi:10.1210/clinem/dgae693 [Level I: Randomized Controlled Trial]
• Wang AY, Tang TK, Yau YY et al. Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial. Am J Kidney Dis. 2024. doi:10.1053/j.ajkd.2023.10.007 [Level I: Randomized Controlled Trial]
• Silverberg SJ, Shane E, Jacobs TP et al. A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery. N Engl J Med. 1999. doi:10.1056/NEJM199910213411701 [Level II: Prospective Cohort Study]
• Ketteler M, Block GA, Evenepoel P et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017. doi:10.1016/j.kisu.2017.04.001 [Level V: Clinical Practice Guideline]

15. Master Class Pro-Tip

The most dangerous and humbling orthopaedic pitfall in metabolic bone disease is mistaking a parathyroid brown tumor for a giant cell tumor of bone (GCTB) or a lytic metastatic malignancy. Histologically, brown tumors and GCTBs display identical sheets of multinucleated osteoclast-like giant cells interspersed among oval-to-spindle mononuclear cells, rendering them virtually indistinguishable on frozen section or core needle biopsy. Plunging into an uncharacterized osteolytic lesion with curettage or wide oncologic resection when the underlying pathology is a brown tumor exposes the patient to severe hemorrhage from hypervascular tissue, iatrogenic fracture, poor implant purchase in osteomalacic bone, and unnecessary structural morbidity. Every surgeon evaluating an expansile, eccentric lytic bone lesion must obtain a routine metabolic laboratory triad: total and ionized calcium, intact parathyroid hormone (iPTH), and alkaline phosphatase. When hyperparathyroidism is identified, the definitive orthopaedic treatment is endocrine: successful parathyroidectomy eliminates the pathological osteoclast drive, prompting rapid, spontaneous re-ossification and complete consolidation of the brown tumor within 6 to 12 months. Reserve surgical stabilization strictly for weight-bearing long bones with impending mechanical collapse (Mirels score ≥ 8), utilizing load-sharing intramedullary fixation rather than curettage. Finally, never discharge these patients postoperatively without aggressive calcium and calcitriol vigilance; patients with extensive skeletal disease and elevated alkaline phosphatase are primed for catastrophic hungry bone syndrome, requiring proactive calcitriol loading and intensive mineral replacement to prevent lethal tetany.

Master Class Surgical Pearl: Musculoskeletal Management of Parathyroid Bone Disease